Biomerica, Inc.

Is Biomerica, Inc. technically bullish or bearish?

As of August 26, 2025, Biomerica, Inc. is in a mildly bearish trend, with bearish signals from the weekly MACD and Bollinger Bands, despite some mildly bullish indicators, and it has underperformed the S&P 500 recently while outperforming it year-to-date and over the past year.

As of 26 August 2025, the technical trend for Biomerica, Inc. has changed from sideways to mildly bearish. The current stance is bearish, driven by the weekly MACD and Bollinger Bands both indicating bearish signals, alongside a bearish daily moving average. The monthly MACD shows a mildly bullish signal, but this is overshadowed by the overall bearish indicators. The KST is mildly bullish on both weekly and monthly timeframes, but Dow Theory indicates a mildly bearish monthly trend. <BR><BR>In terms of performance, Biomerica has underperformed the S&P 500 over the past week and month, with returns of -0.68% and -4.56% compared to 1.05% and 2.33% for the benchmark, respectively. However, it has outperformed the S&P 500 year-to-date and over the past year.

How big is Biomerica, Inc.?

As of Jun 18, Biomerica, Inc. has a market capitalization of 8.30 million, with net sales of 5.69 million and a net profit of -4.85 million over the latest four quarters. The company reported shareholder's funds of 6.59 million and total assets of 9.25 million as of May 24.

Market Cap: As of Jun 18, Biomerica, Inc. has a market capitalization of 8.30 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Biomerica, Inc. reported net sales of 5.69 million and a net profit of -4.85 million.<BR><BR>Balance Sheet Snapshot: As of May 24, the company reported shareholder's funds of 6.59 million and total assets of 9.25 million.

What does Biomerica, Inc. do?

Biomerica, Inc. is a biomedical company that develops and markets medical diagnostic products for chronic diseases. As of February 2025, it has a market cap of $8.30 million, with net sales of $1 million and a net profit of -$1 million.

Overview:<BR>Biomerica, Inc. is a biomedical company that develops, manufactures, and markets medical diagnostic products for the early detection and monitoring of chronic diseases and medical conditions, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 1 Million (Quarterly Results - Feb 2025) <BR>Most recent Net Profit: -1 Million (Quarterly Results - Feb 2025) <BR>Market cap: USD 8.30 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.49 <BR>Return on Equity: -87.64% <BR>Price to Book: 1.50<BR><BR>Contact Details:<BR>Address: 17571 von Karman Ave, IRVINE CA: 92614-6207 <BR>Tel: 1 949 6452111 <BR>Fax: 1 949 5531231 <BR>Website: http://www.biomerica.com/

Should I buy, sell or hold Biomerica, Inc.?

Who are in the management team of Biomerica, Inc.?

As of March 2022, the management team of Biomerica, Inc. includes CEO Zackary Irani, Lead Independent Executive Vice Chairman Allen Barbieri, and Independent Directors Francis Cano, Catherine Coste, Jane Emerson, and Mark Sirgo, who oversee the company's operations and strategy.

As of March 2022, the management team of Biomerica, Inc. includes the following individuals:<BR><BR>- Mr. Zackary Irani, who serves as the Chairman of the Board and Chief Executive Officer.<BR>- Mr. Allen Barbieri, who is the Lead Independent Executive Vice Chairman of the Board and Corporate Secretary.<BR>- Dr. Francis Cano, who is an Independent Director.<BR>- Ms. Catherine Coste, who is also an Independent Director.<BR>- Dr. Jane Emerson, who serves as an Independent Director.<BR>- Dr. Mark Sirgo, who is another Independent Director.<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.